Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Over the last two decades, median overall survival (OS) for patients with metastatic CRC (mCRC) has increased to roughly 30 months due to the improvements in the number and efficacy of systemic therapies. Recently, two novel drugs have been approved for the treatment of chemorefractory mCRC patients such as regorafenib and trifluridine/tipiracil (TAS-102). However, despite their clinical approval, it still remains unclear which of these two drugs should be used first because of a lack of head-to-head randomized trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
